Inhaled corticosteroids in chronic obstructive pulmonary disease: a review

Bibliography

• Global strategy for the Diagnosis, Managment and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Pulmonary Disease. NHLB/WHO workshop report, 2008. Available from: www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003
   Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Chronic obstructive pulmonary disease surveillance–United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL, Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:927-33
   PubMed Web of Science ®Google Scholar
• Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009;34:10-2
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. Inhaled corticosteroids in COPD: a light at the end of the tunnel? Thorax 2005;60:977-8
   Google Scholar
• Suissa S. Inhaled corticosteroids in COPD and mortality: inaccuracies? Am J Respir Crit Care Med 2004;169:1165-6
   Google Scholar
• Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009;374:668-70
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH, Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007:CD002991
   Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53
   PubMed Web of Science ®Google Scholar
• Mirici A, Bektas Y, Ozbakis G, Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease a Randomised,double-blind, placebo-controlled clinical trial. Clin Drug Invest 2001;21:835-42
   Web of Science ®Google Scholar
• Rennard A, Bailey W, Tashkin R, Improvements in airflow and dyspnea in COPD following BID treatment with fluticasone propionate (FP) 250mcg and 500mcg for 24 weeks via the Diskus inhaler. 97th Meeting of the AmericanThoracic Society; 2001
   Google Scholar
• Vestbo J, Sorensen T, Lange P, Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9
   Google Scholar
• Celli BR, Thomas NE, Anderson JA, Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8
   PubMed Web of Science ®Google Scholar
• Lapperre TS, Snoeck-Stroband JB, Gosman MM, Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-27
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-63
   PubMed Web of Science ®Google Scholar
• van Manen J, Bindels P, Dekker F, The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 2003;56:1177-84
   PubMed Web of Science ®Google Scholar
• Stahl E, Lindberg A, Jansson SA, Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005;3:56
   PubMedGoogle Scholar
• Mahler DA, Tomlinson D, Olmstead EM, Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995;151:61-5
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Burge PS, Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702
   PubMed Web of Science ®Google Scholar
• Effing TW, Kerstjens HA, Monninkhof EM, Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest 2009;136:918-23
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S51-S59
   Google Scholar
• Miravitlles M, Murio C, Guerrero T, Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123:784-91
   PubMed Web of Science ®Google Scholar
• Chapman KR, Mannino DM, Soriano JB, Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9
   PubMed Web of Science ®Google Scholar
• de Oca MM, Talamo C, Halbert RJ, Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. Chest 2009;136:71-8
   Google Scholar
• Jones PW, Willits LR, Burge PS, Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73
   PubMed Web of Science ®Google Scholar
• Walters JA, Gibson PG, Wood-Baker R, Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009:CD001288
   PubMed Web of Science ®Google Scholar
• Niewoehner D, Erbland M, Deupree R, Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7
   PubMed Web of Science ®Google Scholar
• de Jong YP, Uil SM, Grotjohan HP, Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007;132:1741-7
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker JJ, Postma DS, Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD 2008;5:282-90
   Google Scholar
• Ställberg B, Selroos O, Vogelmeier C, Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res 2009;10:11-22
   PubMedGoogle Scholar
• Gunen H, Hacievliyagil SS, Yetkin O, The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007;29:660-7
   PubMed Web of Science ®Google Scholar
• Maltais F, Ostinelli J, Bourbeau J, Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703
   PubMed Web of Science ®Google Scholar
• Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1S-4S
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20
   PubMed Web of Science ®Google Scholar
• Lange P, Nyboe J, Appleyard M, Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990;45:579-85
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-9
   PubMed Web of Science ®Google Scholar
• Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503-7
   PubMed Web of Science ®Google Scholar
• Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809-14
   Google Scholar
• Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and comorbidity–a common inflammatory phenotype? Respir Res 2006;7:70
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-9
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Luppi F, Beghe B, Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Ranouil X, Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005;25:634-9
   PubMed Web of Science ®Google Scholar
• Parimon T, Chien JW, Bryson CL, Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:712-9
   PubMed Web of Science ®Google Scholar
• Sin DD, Wu L, Anderson JA, Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7
   PubMed Web of Science ®Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007:CD003794
   Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007:CD006829
   Google Scholar
• Saetta M, Turato G, Maestrelli P, Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53
   PubMed Web of Science ®Google Scholar
• Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000;117:251S-60S
   PubMed Web of Science ®Google Scholar
• Gosman MM, Willemse BW, Jansen DF, Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J 2006;27:60-4
   PubMed Web of Science ®Google Scholar
• van der Strate BW, Postma DS, Brandsma CA, Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006;173:751-8
   PubMed Web of Science ®Google Scholar
• Rutgers SR, Postma DS, ten Hacken NH, Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker JJ, Postma DS, Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 2009;4:101-9
   PubMedGoogle Scholar
• Saetta M, Di Stefano A, Maestrelli P, Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996;26:766-74
   PubMed Web of Science ®Google Scholar
• Barnes NC, Qiu YS, Pavord ID, Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43
   PubMed Web of Science ®Google Scholar
• Boorsma M, Lutter R, van de Pol MA, Long-term effects of budesonide on inflammatory status in COPD. COPD 2008;5:97-104
   PubMedGoogle Scholar
• Bourbeau J, Christodoulopoulos P, Maltais F, Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-43
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hargadon B, Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8
   PubMed Web of Science ®Google Scholar
• Burnett D, Reynolds JJ, Ward RV, Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patients with chronic obstructive bronchitis: effect of corticosteroid treatment. Thorax 1986;41:740-5
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Mainardi E, Della Porta R, Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Maziak W, Loukidis S, Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Kubo K, Yamamoto H, Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999;115:697-702
   PubMed Web of Science ®Google Scholar
• Gizycki MJ, Hattotuwa KL, Barnes N, Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803
   PubMed Web of Science ®Google Scholar
• Hattotuwa KL, Gizycki MJ, Ansari TW, The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-6
   PubMed Web of Science ®Google Scholar
• Keatings VM, Jatakanon A, Worsdell YM, Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71
   PubMed Web of Science ®Google Scholar
• Loppow D, Schleiss MB, Kanniess F, In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-21
   PubMed Web of Science ®Google Scholar
• Ozol D, Aysan T, Solak ZA, The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005;99:1494-500
   PubMed Web of Science ®Google Scholar
• Pizzichini E, Pizzichini MM, Gibson P, Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-7
   PubMed Web of Science ®Google Scholar
• Stockley RA, Morrison HM, Kramps JA, Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment. Thorax 1986;41:442-7
   Google Scholar
• Sugiura H, Ichinose M, Yamagata S, Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax 2003;58:299-305
   PubMed Web of Science ®Google Scholar
• Thompson AB, Mueller MB, Heires AJ, Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992;146:389-95
   PubMed Web of Science ®Google Scholar
• Verhoeven GT, Garrelds IM, Hoogsteden HC, Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2001;10:21-6
   PubMed Web of Science ®Google Scholar
• Verhoeven GT, Hegmans JP, Mulder PG, Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002;57:694-700
   PubMed Web of Science ®Google Scholar
• Wiggins J, Elliott JA, Stevenson RD, Effect of corticosteroids on sputum sol-phase protease inhibitors in chronic obstructive pulmonary disease. Thorax 1982;37:652-6
   Google Scholar
• Yildiz F, Kaur AC, Ilgazli A, Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000;67:71-6
   PubMed Web of Science ®Google Scholar
• Ito K, Ito M, Elliott WM, Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76
   PubMed Web of Science ®Google Scholar
• Ito K, Lim S, Caramori G, Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-2
   PubMedGoogle Scholar
• Cosio BG, Iglesias A, Rios A, Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009;64:424-9
   PubMed Web of Science ®Google Scholar
• Grootendorst D, Rabe K. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1:77-87
   PubMedGoogle Scholar
• Tashkin DP, Altose MD, Bleecker ER, The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 1992;145:301-10
   PubMed Web of Science ®Google Scholar
• Postma DS, de Vries K, Koeter GH, Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986;134:276-80
   PubMed Web of Science ®Google Scholar
• Taylor RG, Joyce H, Gross E, Bronchial reactivity to inhaled histamine and annual rate of decline in FEV1 in male smokers and ex-smokers. Thorax 1985;40:9-16
   PubMed Web of Science ®Google Scholar
• Rijcken B, Schouten JP, Xu X, Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995;151:1377-82
   PubMed Web of Science ®Google Scholar
• Hospers JJ, Postma DS, Rijcken B, Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000;356:1313-7
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Altose MD, Connett JE, Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996;153:1802-11
   PubMed Web of Science ®Google Scholar
• Renkema TE, Kerstjens HA, Schouten JP, The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD. Clin Exp Allergy 1998;28:1210-8
   Google Scholar
• Engel T, Heinig JH, Madsen O, A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989;2:935-9
   PubMed Web of Science ®Google Scholar
• Auffarth B, Postma DS, de Monchy JG, Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991;46:372-7
   PubMed Web of Science ®Google Scholar
• van Grunsven P, Schermer T, Akkermans R, Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respir Med 2003;97:1303-12
   PubMed Web of Science ®Google Scholar
• Soriano JB, Sin DD, Zhang X, A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-9
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Emmett A, Crater G, Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008;21:682-8
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Fujimoto K, Kubo K, Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 2006;100:1742-52
   PubMed Web of Science ®Google Scholar
• Reid DW, Wen Y, Johns DP, Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology 2008;13:799-809
   PubMedGoogle Scholar
• Perng DW, Wu CC, Su KC, Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Lung 2006;184:217-22
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13
   PubMed Web of Science ®Google Scholar
• Leuppi JD, Tandjung R, Anderson SD, Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther 2005;18:83-8
   PubMed Web of Science ®Google Scholar
• Rutgers SR, Koeter GH, van der Mark TW, Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5’-monophosphate in COPD. Am J Respir Crit Care Med 1998;157:880-6
   PubMed Web of Science ®Google Scholar
• McGraw DW, Liggett SB. Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor. J Biol Chem 1997;272:7338-44
   PubMed Web of Science ®Google Scholar
• Kalavantavanich K, Schramm CM. Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000;278:L1101-6
   Web of Science ®Google Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268:L41-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-91
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R, Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10
   PubMed Web of Science ®Google Scholar
• Profita M, Gagliardo R, Di GR, Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 2005;60:323-9
   PubMed Web of Science ®Google Scholar
• Roth M, Johnson PR, Rudiger JJ, Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002;360:1293-9
   PubMed Web of Science ®Google Scholar
• Jones A, Fay JK, Burr M, Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002:CD003537
   Google Scholar
• Smeeth L, Boulis M, Hubbard R, A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003;87:1247-51
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-29
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X, Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-9
   PubMed Web of Science ®Google Scholar
• Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009;122:472-8
   PubMed Web of Science ®Google Scholar
• Capewell S, Reynolds S, Shuttleworth D, Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51
   PubMed Web of Science ®Google Scholar
• Kim WJ, Sheen SS, Kim TH, Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology 2009;14:260-3
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Boushey HA, Dolganov GM, Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858-63
   PubMed Web of Science ®Google Scholar